OPIANT PHARMACEUTICALS
Opiant Pharmaceuticals, with its team of addiction experts, is headquartered in Santa Monica, California. The Company, formerly known as Lightlake Therapeutics, was founded in 2009 by the late Dr. David Sinclair based on his pioneering research demonstrating that opioid antagonists could be used as a symptom-driven treatment for alcoholism
OPIANT PHARMACEUTICALS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2009-01-01
Address:
Santa Monica, California, United States
Country:
United States
Website Url:
http://www.opiant.com
Status:
Active
Contact:
+1 310 598 5410
Email Addresses:
[email protected]
Total Funding:
52 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon WordPress Google Universal Analytics Sitelinks Search Box Organization Schema Yoast WordPress SEO Plugin
Similar Organizations
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Frontier Biotechnologies
Frontier Biotechnologies is a commercial-stage bio-pharmaceutical company.
Leap Therapeutics
Leap Therapeutics is a clinical-stage biopharmaceutical company.
Oclassen Pharmaceuticals
Oclassen Pharmaceuticals, Inc. was acquired by Watson Pharmaceuticals Inc.
Saol Therapeutics
Saol Therapeutics is a biotech pharmaceutical company.
Current Advisors List
Current Employees Featured
Investors List
Biomedical Advanced Research and Development Authority (BARDA)
Biomedical Advanced Research and Development Authority (BARDA) investment in Grant - Opiant Pharmaceuticals
Pontifax
Pontifax investment in Debt Financing - Opiant Pharmaceuticals
Official Site Inspections
http://www.opiant.com Semrush global rank: 4.99 M Semrush visits lastest month: 1.69 K
- Host name: 45.60.31.106
- IP address: 45.60.31.106
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Opiant Pharmaceuticals"
Indivior to Acquire Opiant Pharmaceuticals
Nov 14, 2022 “This transaction combines Opiant with an organization that shares our patient-focused mindset, and we believe creates immediate value for patients, our employees and our …See details»
Indivior Completes Acquisition of Opiant Pharmaceuticals, Inc.
On November 13, 2022, Indivior and Opiant entered into a definitive agreement under which Indivior would acquire Opiant for an upfront consideration of $20.00 per share, in cash …See details»
Opiant Pharmaceuticals - Crunchbase Company Profile & Funding
Opiant Pharmaceuticals is a pharmaceutical company that develops treatments for drug overdose and addictions leveraging intranasal and injectable delivery technologies. The company, …See details»
Indivior Completes Acquisition of Opiant …
Mar 2, 2023 Opiant announced the completion of its rolling NDA (New Drug Application) submission for OPNT003 on December 22, 2022. A PDUFA (Prescription Drug User Fee Action) date for OPNT003 has been set by ...See details»
Opiant Pharmaceuticals, Inc. - AnnualReports.com
Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. Visit website. REPORT RATINGS. 4.8 / 5.0 (150) Opiant …See details»
Opiant Pharmaceuticals - Craft
Mar 2, 2023 Opiant Pharmaceuticals is a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders. The Company …See details»
Opiant, maker of Narcan, to be acquired in $145 million deal
Nov 14, 2022 Opiant plans to complete the submission to the Food and Drug Administration for that drug by the end of the year. Indivior's upfront payment of $20.00 per share is a premium …See details»
Indivior | Our Leadership - Opiant
During her tenure she led multiple executive and organization transformations, mergers and divestitures, and implemented a highly effective CEO and executive succession program. Under Angela, Otsuka received recognition as a Great …See details»
US FDA approves Opiant's spray for reversing opioid …
May 22, 2023 The U.S. Food and Drug Administration on Monday approved Opiant Pharmaceuticals Inc's nasal spray for reversing opioid-related overdoses, expanding treatment options in the country's fight against ...See details»
Opiant Pharmaceuticals Announces Fourth Quarter and Full-Year …
SANTA MONICA, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to …See details»
Indivior To Acquire Opiant Pharmaceuticals - BioSpace
Nov 14, 2022 Indivior PLC and Opiant Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which Indivior will acquire Opiant for an upfront …See details»
OPNT: Raises 2021 Full-Year Revenue and Cash Guidance...
Nov 15, 2021 Opiant is now forecasting full year royalty revenue of $38 million. Net income for the three months ending September 30, 2021 was approximately $3.4 million, or $0.77 per …See details»
Indivior To Acquire Opiant Pharmaceuticals - PR Newswire
Nov 14, 2022 Under the terms of the merger agreement, Indivior will acquire all outstanding shares of Opiant for upfront consideration of $20.00 per share in cash, plus up to $8.00 per …See details»
Together We’re Working To Change Lives - Opiant
Contents Strategic Report 2 Financial Highlights 3 Introduction 4 Who We Are 6 Disease State 7 Purpose in Action 12 Chair’s Statement 14 Chief Executive Officer’s Review 19 Chief Scientific …See details»
Opiant Pharmaceuticals Announces Third Quarter 2022 Financial …
Nov 14, 2022 Financial Results for the Three Months Ended September 30, 2022 . For the three months ended September 30, 2022, Opiant recorded $0.2 million of revenue, compared to …See details»
FOR IMMEDIATE RELEASE - Opiant
Nov 14, 2022 Indivior To Acquire Opiant Pharmaceuticals . Acquisition Strengthens and Extends Indivior’s Position as a Leader in Addiction Treatment . ... and a R&D organization that has …See details»
Opiant Pharmaceuticals Announces First Patient Dosed in
Jan 20, 2022 Phase 2 trial to evaluate reduction in heavy drinking as measured by a change in the World Health Organization drinking risk levels 1; Trial is informed by results from Phase 1 …See details»
Indivior Charitable Contributions, Corporate Membership, and
The size, scope, reputation and expertise of the requesting Organization; Whether the purpose of the CCMC is consistent with the Group's areas of giving and corporate mission; Whether the …See details»
Opiant Pharmaceuticals Announces First Quarter 2022 Financial …
SANTA MONICA, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to …See details»